Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma

Ahmed I Tahseen; Neel B Patel

doi:10.1016/j.jdcr.2018.08.003

Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma

JAAD Case Rep. 2018 Oct 10;4(9):930-933. doi: 10.1016/j.jdcr.2018.08.003. eCollection 2018 Oct.

Authors

Ahmed I Tahseen¹, Neel B Patel²

Affiliations

¹ Creighton University School of Medicine, Phoenix Regional Campus, Phoenix, Arizona.
² Southwest Skin Specialists, Phoenix, Arizona.

No abstract available

Keywords: BRAF inhibitor; BRAF inhibitor Stevens-Johnson syndrome; BRAF inhibitor toxic epidermal necrolysis; LTT, lymphocyte transformation test; NO, nitric oxide; RIP3, receptor-interacting protein kinase 3; SJS, Stevens-Johnson syndrome; Stevens-Johnson syndrome; Stevens-Johnson syndrome desensitization; TEN, toxic epidermal necrolysis; allergic reaction; antitumor response; antitumor response toxic epidermal necrolysis; coBRIM adverse effect; coBRIM allergic reaction; coBRIM hypersensitivity; coBRIM, combined cobimetinib and vemurafenib therapy; cross-reactivity; dabrafenib; dabrafenib toxic epidermal necrolysis; dabrafenib vemurafenib; dabrafenib vemurafenib switch; hypersensitivity; lymphocyte transformation test Stevens-Johnson syndrome; lymphocyte transformation test toxic epidermal necrolysis; melanoma; metastatic melanoma; sulfonamide; sulfonamide cross-reactivity; sulfonamide drug; sulfonamide toxic epidermal necrolysis; toxic epidermal necrolysis; toxic epidermal necrolysis desensitization; toxic epidermal necrolysis/Stevens-Johnson syndrome; vemurafenib; vemurafenib adverse effect; vemurafenib allergic reaction; vemurafenib dabrafenib cross-reactivity; vemurafenib hypersensitivity; vemurafenib toxic epidermal necrolysis.

Publication types

Case Reports